Read More 1 minute read Analyst Color Analyst Ratings News Price Target New Indication Approval For Incyte “To Usher New Growth Avenue” By Vandana Singh July 21, 1:03 PM JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ:INCY) based on… INCY
Read More 1 minute read Analyst Color Analyst Ratings Downgrades Price Target Why This DocuSign Analyst Says There’s Downside Ahead By Priya Nigam July 21, 12:35 PM DocuSign Inc (NASDAQ: DOCU) has an elevated risk profile given the CEO transition, execution challenges, high employee turnover and a deteriorating macro environment, according to Piper Sandler. ADBE
Read More 1 minute read Analyst Ratings Initiation News Price Target Keybanc Initiates Coverage On Nordstrom with Overweight Rating, Announces Price Target of $30 By Benzinga Newsdesk July 21, 12:14 PM Keybanc analyst Noah Zatzkin initiates coverage on Nordstrom (NYSE:JWN) with a Overweight rating and announces Price Target of $30. JWN
Read More 1 minute read Analyst Ratings News Price Target DA Davidson Maintains Buy on Overstock.com, Lowers Price Target to $116 By Benzinga Newsdesk July 21, 10:31 AM DA Davidson analyst Tom Forte maintains Overstock.com (NASDAQ:OSTK) with a Buy and lowers the price target from $145 to $116. OSTK
Read More 1 minute read Analyst Ratings News Price Target Baird Maintains Outperform on Bath & Body Works, Lowers Price Target to $40 By Benzinga Newsdesk July 21, 10:27 AM Baird analyst Mark Altschwager maintains Bath & Body Works (NYSE:BBWI) with a Outperform and lowers the price target from $50 to $40. BBWI
Read More 1 minute read Analyst Ratings News Price Target Cowen & Co. Maintains Market Perform on CSX, Lowers Price Target to $37 By Benzinga Newsdesk July 21, 10:24 AM Cowen & Co. analyst Jason Seidl maintains CSX (NASDAQ:CSX) with a Market Perform and lowers the price target from $39 to $37. CSX
Read More 1 minute read Analyst Ratings News Price Target Cowen & Co. Maintains Outperform on Biogen, Lowers Price Target to $270 By Benzinga Newsdesk July 21, 10:22 AM Cowen & Co. analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $285 to $270. BIIB
Read More 1 minute read Analyst Ratings News Price Target Wedbush Maintains Neutral on Deckers Outdoor, Raises Price Target to $312 By Benzinga Newsdesk July 21, 10:18 AM Wedbush analyst Tom Nikic maintains Deckers Outdoor (NYSE:DECK) with a Neutral and raises the price target from $292 to $312. DECK
Read More 1 minute read Analyst Ratings News Price Target Wedbush Maintains Outperform on Comerica, Raises Price Target to $94 By Benzinga Newsdesk July 21, 10:15 AM Wedbush analyst Peter Winter maintains Comerica (NYSE:CMA) with a Outperform and raises the price target from $89 to $94. CMA
Read More 1 minute read Analyst Ratings News Price Target Canaccord Genuity Maintains Buy on Tesla, Raises Price Target to $815 By Benzinga Newsdesk July 21, 10:13 AM Canaccord Genuity analyst George Gianarikas maintains Tesla (NASDAQ:TSLA) with a Buy and raises the price target from $801 to $815. TSLA